<- Go Home
Vaccinogen, Inc.
Vaccinogen, Inc., a biotechnology company, focuses on the development and commercialization of cancer vaccines and immunotherapeutic products for cancers in the United States. It primarily offers OncoVAX, a cancer vaccine for the post-surgical treatment of Stage II colon cancer. The company was founded in 2007 and is headquartered in Baltimore, Maryland.
Market Cap
$3.7K
Volume
8.1K
Cash and Equivalents
$445.8K
EBITDA
-$21.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.00
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.00
Price / Earnings
-0.00
Price / Tangible Book Value
-0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$28.6M
Return on Equity
60.68%
Return on Assets
-29.51
Cash and Short Term Investments
$445.8K
Debt
$3.8M
Equity
$39.7M
Revenue
N/A
Unlevered FCF
-$3.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium